[
    "lactose. </p>TabletsActive substance20.0mgMaize starch25.0mgLactose190.0mgGelatin1.5mgTalc12.0mgMagnesium stearate1.5mg350.mg</p>SuppositoriesActive Substance50.0mgAscorbyl palmitate1.0mgSuppository base (Imhausen H)ad 2000.0mg</p>Injection SolutionActive substance2.000mgSodium hydroxide0.310mgSodium purosulphite0.500mgDisodium edetate0.100mgSodium chloride8.500mgSterile water for injectionad 1.00g</p>EXAMPLE 2This example compares the potency and selectivity towards various adenosine receptors of a compound of formula (I) wherein R is pyrrolidino to the potency and selectivity of theophylline, DPSPX (1,3-dipropyl-8-p-sulfophenylxanthine), and enprofylline.</p>Antagonist potency (K<sub>1 </sub>or K<sub>B</sub>, \u03bcM)A<sub>1</sub>A<sub>2A </sub>A<sub>2B </sub>A<sub>3 </sub>CompoundReceptorReceptorReceptorReceptorTheophylline8.5<sup>1</sup>(r)25<sup>2</sup>(r)5<sup>3</sup>(h)&gt;100<sup>9</sup>(r)DPSPX0.14<sup>1</sup>(r)0.79<sup>2</sup>(r)0.14<sup>3</sup>(h)&gt;100<sup>9</sup>(r)Enprofylline156<sup>4</sup>(h)32<sup>5</sup>(h)7<sup>3.6</sup>(h)56<sup>10</sup>(h)Formula (I)31<sup>7</sup>(h)20<sup>8</sup>(h)0.525<sup>3</sup>(h)53<sup>11</sup>(h)<sup>1</sup>Displacement of [<sup>3</sup>H] PIA binding from rat brain membranes. (See A. S. Rovena et al. Drug Dev. Res. 39: 243-252 (1996) and Ukena et al. Febs Letters 209: 122-128 (1986)). <sup>2</sup>Displacement of [<sup>3</sup>] CGS 21680 from rat striatal membranes. (See I. Hide et al. Mol. Pharmacol. 41: 352-359 (1992)). <sup>3</sup>Inhibition of NECA-stimulated cAMP in HEL cells. (See I. Feoktistov and I. Biaggioni. Mol. Pharmacol. 43: 909-914 (1993)). <sup>4</sup>Displacement of [<sup>3</sup>H] DPCPX from membranes of HEK-293 cells transfected with human A<sub>1</sub>. (See J. Linden et al. Life Science. 62: 1519-1524 (1998)). <sup>5</sup>Displacement of [<sup>3</sup>H] CGS 21680 from membranes of HEK-293 cells transfected with human A<sub>2A</sub>. (See A. S. Rovena et al. Drug Dev. Res. 39: 243-252 (1996)). <sup>6</sup>Displacement of [<sup>3</sup>H] 1,3-diethyl-8-phenylxanthine from membranes of HEK-293 cells transfected with human A<sub>2A</sub>. (See A. S. Rovena et al. Drug Dev. Res. 39: 243-252 (1996)). <sup>7</sup>Displacement with [<sup>3</sup>] DPCPX from membranes of CHO cells transfected with human A<sub>1</sub>. (See K. N. Klotz, et al. N-S Arch. Pharmacol. 357: 1-9 (1998)) <sup>8</sup>Inhibition of CGS 21680-stimulated cAMP in HMC-1 cells. (See I. Feoktistov, and I. Biaggioni, Biochem. Pharmacol. 55: 627-633 (1998)). <sup>9</sup>Displacement of [125I] APNEA from membranes of CHO cells transfected with rat A3 (see P. J. van Galen, et. al. Mol. Pharmacol. 45: 1101-1111 (1994)). <sup>10</sup>Displacement of [125I] ABA from membranes of HEK-293 cells transfected with human A3 (see J. A. Auchampach, et al. Mol. Pharmacol. 52: 846-860 (1997)). <sup>11</sup>Displacement of [3H] NECA from CHO cells transfected with human A3 (see K. N. Klotz, et al. N-S. Arch Pharmacol. 357: 1-9 (1998)). </p>As can be seen from the above table, compounds of formula (I) wherein R is pyrrolidino have potencies much higher than that of enprofylline, for example, and are 40- to 60-fold selective compared to A<sub>2A </sub>and A<sub>1</sub>.</p>All cited patents and publications referred to in this application are herein expressly incorporated by reference.</p>This invention thus being described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one of ordinary skill in the art are intended to be included within the scope of the following claims.</p>"
]